vs

Side-by-side financial comparison of Anghami Inc (ANGH) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

STANDARD BIOTOOLS INC. is the larger business by last-quarter revenue ($19.6M vs $18.9M, roughly 1.0× Anghami Inc). Anghami Inc runs the higher net margin — -63.2% vs -177.4%, a 114.2% gap on every dollar of revenue.

Anghami is the first legal music streaming platform and digital distribution company in the Arab world. It launched in November 2012 in Lebanon, providing unlimited Arabic and international music to stream and download for offline mode.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

ANGH vs LAB — Head-to-Head

Bigger by revenue
LAB
LAB
1.0× larger
LAB
$19.6M
$18.9M
ANGH
Higher net margin
ANGH
ANGH
114.2% more per $
ANGH
-63.2%
-177.4%
LAB

Income Statement — Q2 FY2024 vs Q3 FY2025

Metric
ANGH
ANGH
LAB
LAB
Revenue
$18.9M
$19.6M
Net Profit
$-12.0M
$-34.7M
Gross Margin
17.4%
48.5%
Operating Margin
-52.2%
-168.5%
Net Margin
-63.2%
-177.4%
Revenue YoY
-11.5%
Net Profit YoY
-28.8%
EPS (diluted)
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ANGH
ANGH
LAB
LAB
Q3 25
$19.6M
Q2 25
$21.8M
Q1 25
$40.8M
Q3 24
$22.1M
Q2 24
$18.9M
$22.5M
Q1 24
$45.5M
Q4 23
$28.2M
Q3 23
$25.4M
Net Profit
ANGH
ANGH
LAB
LAB
Q3 25
$-34.7M
Q2 25
$-33.5M
Q1 25
$-26.0M
Q3 24
$-26.9M
Q2 24
$-12.0M
$-45.7M
Q1 24
$-32.2M
Q4 23
$-19.8M
Q3 23
$-21.0M
Gross Margin
ANGH
ANGH
LAB
LAB
Q3 25
48.5%
Q2 25
48.8%
Q1 25
48.4%
Q3 24
54.9%
Q2 24
17.4%
46.1%
Q1 24
53.1%
Q4 23
47.6%
Q3 23
44.0%
Operating Margin
ANGH
ANGH
LAB
LAB
Q3 25
-168.5%
Q2 25
-118.1%
Q1 25
-80.8%
Q3 24
-120.9%
Q2 24
-52.2%
-134.5%
Q1 24
-132.2%
Q4 23
-75.9%
Q3 23
-83.5%
Net Margin
ANGH
ANGH
LAB
LAB
Q3 25
-177.4%
Q2 25
-153.7%
Q1 25
-63.8%
Q3 24
-122.0%
Q2 24
-63.2%
-203.3%
Q1 24
-70.6%
Q4 23
-70.2%
Q3 23
-82.8%
EPS (diluted)
ANGH
ANGH
LAB
LAB
Q3 25
$-0.09
Q2 25
$-0.09
Q1 25
$-0.07
Q3 24
$-0.07
Q2 24
$-0.12
Q1 24
$-0.27
Q4 23
$-0.24
Q3 23
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ANGH
ANGH
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$26.9M
$129.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$94.6M
$399.7M
Total Assets
$143.1M
$539.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ANGH
ANGH
LAB
LAB
Q3 25
$129.4M
Q2 25
$158.6M
Q1 25
$150.9M
Q3 24
$210.6M
Q2 24
$26.9M
$269.8M
Q1 24
$287.1M
Q4 23
$51.7M
Q3 23
$79.7M
Total Debt
ANGH
ANGH
LAB
LAB
Q3 25
Q2 25
Q1 25
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Q4 23
$63.5M
Q3 23
$64.6M
Stockholders' Equity
ANGH
ANGH
LAB
LAB
Q3 25
$399.7M
Q2 25
$424.5M
Q1 25
$454.6M
Q3 24
$489.3M
Q2 24
$94.6M
$510.3M
Q1 24
$577.3M
Q4 23
$-148.1M
Q3 23
$-131.7M
Total Assets
ANGH
ANGH
LAB
LAB
Q3 25
$539.6M
Q2 25
$557.0M
Q1 25
$579.6M
Q3 24
$681.5M
Q2 24
$143.1M
$708.7M
Q1 24
$777.7M
Q4 23
$323.1M
Q3 23
$339.3M
Debt / Equity
ANGH
ANGH
LAB
LAB
Q3 25
Q2 25
Q1 25
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×
Q4 23
Q3 23

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ANGH
ANGH
LAB
LAB
Operating Cash FlowLast quarter
$-22.2M
Free Cash FlowOCF − Capex
$-23.1M
FCF MarginFCF / Revenue
-118.1%
Capex IntensityCapex / Revenue
4.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ANGH
ANGH
LAB
LAB
Q3 25
$-22.2M
Q2 25
$-20.7M
Q1 25
$-30.3M
Q3 24
$-27.9M
Q2 24
$-39.0M
Q1 24
$-62.5M
Q4 23
$-14.1M
Q3 23
$-11.4M
Free Cash Flow
ANGH
ANGH
LAB
LAB
Q3 25
$-23.1M
Q2 25
$-22.6M
Q1 25
$-35.3M
Q3 24
$-30.1M
Q2 24
$-41.0M
Q1 24
$-63.3M
Q4 23
$-14.1M
Q3 23
$-12.3M
FCF Margin
ANGH
ANGH
LAB
LAB
Q3 25
-118.1%
Q2 25
-103.6%
Q1 25
-86.6%
Q3 24
-136.4%
Q2 24
-182.2%
Q1 24
-138.9%
Q4 23
-50.2%
Q3 23
-48.6%
Capex Intensity
ANGH
ANGH
LAB
LAB
Q3 25
4.5%
Q2 25
8.7%
Q1 25
12.4%
Q3 24
10.2%
Q2 24
8.6%
Q1 24
1.7%
Q4 23
0.3%
Q3 23
3.6%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ANGH
ANGH

Segment breakdown not available.

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons